BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 146] [Article Influence: 36.5] [Reference Citation Analysis]
Number Citing Articles
1 Hu B, Yang X, Sang X. Liver graft rejection following immune checkpoint inhibitors treatment: a review. Med Oncol 2019;36. [DOI: 10.1007/s12032-019-1316-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
2 Simoneau E, D'Angelica M, Halazun KJ. Liver transplantation for colorectal liver metastasis. Curr Opin Organ Transplant 2019;24:175-81. [PMID: 30839338 DOI: 10.1097/MOT.0000000000000623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
3 Ferrer-Fàbrega J, Sampson-Dávila J, Forner A, Sapena V, Díaz A, Vilana R, Navasa M, Fondevila C, Miquel R, Ayuso C, García-Valdecasas JC, Bruix J, Reig M, Fuster J. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. J Hepatol 2021:S0168-8278(21)00435-9. [PMID: 34171433 DOI: 10.1016/j.jhep.2021.06.015] [Reference Citation Analysis]
4 Wang J, Li Y, Wang R, Han C, Xu S, You T, Li Y, Xia J, Xu X, Wang D, Tang H, Yang C, Chen X, Peng Z. A Fully Automated and Integrated Microfluidic System for Efficient CTC Detection and Its Application in Hepatocellular Carcinoma Screening and Prognosis. ACS Appl Mater Interfaces 2021;13:30174-86. [PMID: 34142547 DOI: 10.1021/acsami.1c06337] [Reference Citation Analysis]
5 Iesari S, Inostroza Núñez ME, Rico Juri JM, Ciccarelli O, Bonaccorsi-Riani E, Coubeau L, Laterre PF, Goffette P, De Reyck C, Lengelé B, Gianello P, Lerut J. Adult-to-adult living-donor liver transplantation: The experience of the Université catholique de Louvain. Hepatobiliary Pancreat Dis Int 2019;18:132-42. [PMID: 30850341 DOI: 10.1016/j.hbpd.2019.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
6 Lee HL, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK, Choi HJ, Na GH, You YK, Park IY, Kim DG. Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2021. [PMID: 34374192 DOI: 10.1002/lt.26258] [Reference Citation Analysis]
7 Sanduzzi-Zamparelli M, Rimola J, Montironi C, Nunes V, Alves VAF, Sapena V, da Fonseca LG, Forner A, Carrilho FJ, Díaz A, Fuster C, Ferrer J, Fuster J, Ayuso C, Solé M, Bruix J, Reig M; Epithelioid Hemangioendothelioma International Network (EHIN). Hepatic epithelioid hemangioendothelioma: An international multicenter study. Dig Liver Dis 2020;52:1041-6. [PMID: 32535084 DOI: 10.1016/j.dld.2020.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma. Dig Dis Sci 2019;64:269-80. [PMID: 30259282 DOI: 10.1007/s10620-018-5296-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Feng Y, Han Z, Feng Z, Wang B, Cheng H, Yang L, Li Y, Gu B, Li X, Li Y, Li Y, Wang C, Chen H. Approaching treatment for immunological rejection of living-donor liver transplantation in rats. BMC Gastroenterol 2020;20:7. [PMID: 31931737 DOI: 10.1186/s12876-019-1130-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Seydi E, Rahimpour Z, Salimi A, Pourahmad J. Selective toxicity of chrysin on mitochondria isolated from liver of a HCC rat model. Bioorg Med Chem. 2019;27:115163. [PMID: 31708277 DOI: 10.1016/j.bmc.2019.115163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018;24:294-303. [PMID: 29024405 DOI: 10.1002/lt.24955] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
12 Wang W, Zhang M, Peng Y, He J. Ubiquitin Associated Protein 2-Like (UBAP2L) Overexpression in Patients with Hepatocellular Carcinoma and its Clinical Significance. Med Sci Monit 2017;23:4779-88. [PMID: 28981479 DOI: 10.12659/msm.907071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 [PMID: 34621472 DOI: 10.4240/wjgs.v13.i9.953] [Reference Citation Analysis]
14 Eom JA, Kwon GH, Kim NY, Park EJ, Won SM, Jeong JJ, Raja G, Gupta H, Asmelash Gebru Y, Sharma S, Choi YR, Kim HS, Yoon SJ, Hyun JY, Jeong MK, Park HJ, Min BH, Choi MR, Kim DJ, Suk KT. Diet-Regulating Microbiota and Host Immune System in Liver Disease. Int J Mol Sci 2021;22:6326. [PMID: 34199182 DOI: 10.3390/ijms22126326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ma D, Gao X, Liu Z, Lu X, Ju H, Zhang N. Exosome-transferred long non-coding RNA ASMTL-AS1 contributes to malignant phenotypes in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Cell Prolif 2020;53:e12795. [PMID: 32722884 DOI: 10.1111/cpr.12795] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
16 Renner P, Da Silva T, Schnitzbauer AA, Verloh N, Schlitt HJ, Geissler EK. Hepatocellular carcinoma progression during bridging before liver transplantation. BJS Open 2021;5:zrab005. [PMID: 33839747 DOI: 10.1093/bjsopen/zrab005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, Ghanekar A, Greig PD, McGilvray ID, Selzner M, Cattral MS, Grant DR, Lilly LB, Selzner N, Renner EL, Sherman M, Sapisochin G. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol 2019;70:866-73. [PMID: 30615906 DOI: 10.1016/j.jhep.2018.12.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
18 Huang LF, Wan P, Xu DW, Jeong S, Feng MX, Zhang JJ, Xia Q. Nomogram predicting pulmonary metastasis of hepatocellular carcinoma after liver transplantation. Oncotarget 2018;9:2425-34. [PMID: 29416782 DOI: 10.18632/oncotarget.23418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
19 Lv Y, Wei W, Huang Z, Chen Z, Fang Y, Pan L, Han X, Xu Z. Long non-coding RNA expression profile can predict early recurrence in hepatocellular carcinoma after curative resection: LncRNA expression profile to predict HCC recurrence. Hepatol Res 2018;48:1140-8. [DOI: 10.1111/hepr.13220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
20 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
21 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Xie YL, Yang Z, Feng X, Yang Q, Ye LS, Li XB, Tang H, Zhang YC, Liu W, Tong Zhang, Fu BS, Yi SH, Yang Y, Chen GH. Association of phenotypic transformation of circulating tumor cells and early recurrence in patients with hepatocellular carcinoma following liver transplantation. Asian J Surg 2021:S1015-9584(21)00477-2. [PMID: 34426060 DOI: 10.1016/j.asjsur.2021.07.058] [Reference Citation Analysis]
23 Liu H, Cen D, Yu Y, Wang Y, Liang X, Lin H, Cai X. Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: evidence from the SEER database? BMC Cancer 2018;18:1125. [PMID: 30445928 DOI: 10.1186/s12885-018-4996-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Jiang Z, Jiang Q, Fang X, Wang P, Que W, Li H, Yu Y, Liu X, Wang C, Zhong L. Recipient C7 rs9292795 genotype and the risk of hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population. BMC Cancer 2021;21:521. [PMID: 33964921 DOI: 10.1186/s12885-021-08269-7] [Reference Citation Analysis]
25 Bhatti ABH, Qureshi AI, Tahir R, Dar FS, Khan NY, Zia HH, Riyaz S, Rana A. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma. BMC Cancer. 2020;20:754. [PMID: 32787864 DOI: 10.1186/s12885-020-07238-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
26 Weller A, Seyfried T, Ahrens N, Baier-Kleinhenz L, Schlitt HJ, Peschel G, Graf BM, Sinner B. Cell Salvage During Liver Transplantation for Hepatocellular Carcinoma: A Retrospective Analysis of Tumor Recurrence Following Irradiation of the Salvaged Blood. Transplant Proc 2021;53:1639-44. [PMID: 33994180 DOI: 10.1016/j.transproceed.2021.03.025] [Reference Citation Analysis]
27 Sokolich J, Buggs J, LaVere M, Robichaux K, Rogers E, Nyce S, Kumar A, Bowers V. HCC Liver Transplantation Wait List Dropout Rates Before and After the Mandated 6-Month Wait Time. Am Surg 2020;86:1592-5. [PMID: 32812771 DOI: 10.1177/0003134820942165] [Reference Citation Analysis]
28 Zhang W, Liu Z, Chen J, Dong S, Cen B, Zheng S, Xu X. A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria. Transl Oncol 2021;14:101200. [PMID: 34399173 DOI: 10.1016/j.tranon.2021.101200] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S;  Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int. 2019;32:356-368. [PMID: 30556935 DOI: 10.1111/tri.13391] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
30 Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019;69:1193-205. [PMID: 30548884 DOI: 10.1002/hep.30413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
31 Bhatti ABH, Dar FS, Qureshi AI, Khan NY, Zia HH, Haider S, Shah NH, Rana A. Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience from Pakistan. J Clin Exp Hepatol 2019;9:704-9. [PMID: 31889751 DOI: 10.1016/j.jceh.2019.04.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25(25): 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
33 Oldani G, Peloso A, Lacotte S, Meier R, Toso C. Xenogeneic chimera-Generated by blastocyst complementation-As a potential unlimited source of recipient-tailored organs. Xenotransplantation 2017;24. [PMID: 28736957 DOI: 10.1111/xen.12327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
34 Foerster F, Mittler J, Darstein F, Heise M, Marquardt JU, Wörns MA, Weinmann A, Sälter L, Hoppe-Lotichius M, Heinrich S, Kloeckner R, Pitton MB, Schattenberg JM, Sprinzl MF, Düber C, Otto G, Lang H, Galle PR, Zimmermann T. Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. Eur J Intern Med 2018;55:57-65. [PMID: 29859798 DOI: 10.1016/j.ejim.2018.05.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
35 Maccali C, Chagas AL, Boin I, Quiñonez E, Marciano S, Vilatobá M, Varón A, Anders M, Hoyos Duque S, Lima AS, Menendez J, Padilla‐machaca M, Poniachik J, Zapata R, Maraschio M, Chong Menéndez R, Muñoz L, Arufe D, Figueroa R, Soza A, Fauda M, Perales SR, Vergara Sandoval R, Bermudez C, Beltran O, Arenas Hoyos I, Mccormack L, Mattera FJ, Gadano A, Parente García JH, Tani CM, Augusto Carneiro D’albuquerque L, Carrilho FJ, Silva M, Piñero F. Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort. Liver Int 2021;41:851-62. [DOI: 10.1111/liv.14736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Cacicedo ML, Medina-Montano C, Kaps L, Kappel C, Gehring S, Bros M. Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells 2020;9:E1985. [PMID: 32872352 DOI: 10.3390/cells9091985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018;24:327-329. [PMID: 29351366 DOI: 10.1002/lt.25017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Song T, Wang C, Guo C, Liu Q, Zheng X. Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer 2018;9:2650-8. [PMID: 30087705 DOI: 10.7150/jca.25188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
39 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Afroz F, Kist A, Hua J, Zhou Y, Sokoya EM, Padbury R, Nieuwenhuijs V, Barritt G. Rapamycin induces the expression of heme oxygenase-1 and peroxyredoxin-1 in normal hepatocytes but not in tumorigenic liver cells.Exp Mol Pathol. 2018;105:334-344. [PMID: 30290159 DOI: 10.1016/j.yexmp.2018.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 da Silva EFG, Lima KG, Krause GC, Haute GV, Pedrazza L, Catarina AV, Gassen RB, de Souza Basso B, Dias HB, Luft C, Garcia MCR, Costa BP, Antunes GL, Basso LA, Donadio MVF, Machado P, de Oliveira JR. CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence. Invest New Drugs 2020;38:1653-63. [DOI: 10.1007/s10637-020-00941-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Reference Citation Analysis]
43 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
44 Yang Z, Zhang L, Zhu H, Zhou K, Wang H, Wang Y, Su R, Guo D, Zhou L, Xu X, Song P, Zheng S, Xie H. Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast. J Cell Mol Med 2021;25:3511-23. [PMID: 33713546 DOI: 10.1111/jcmm.16434] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
45 Chen S, Wu Y, Qi H, Shen L, Ma W, Cao F, Diao Y, Wang T, Ou S, Fan W. Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy. Int J Hyperthermia 2021;38:120-9. [PMID: 33541160 DOI: 10.1080/02656736.2021.1876930] [Reference Citation Analysis]
46 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1001] [Article Influence: 526.7] [Reference Citation Analysis]
47 Jia J, Nie Y, Geng L, Li J, Liu J, Peng Y, Huang J, Xie H, Zhou L, Zheng SS. Identification of HO-1 as a novel biomarker for graft acute cellular rejection and prognosis prediction after liver transplantation. Ann Transl Med 2020;8:221. [PMID: 32309368 DOI: 10.21037/atm.2020.01.59] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
49 Vining CC, Ecker BL, Abt PL, Olthoff KM. Donation after cardiac death in the hepatocellular carcinoma patient: Same indication?: Supplement. Liver Transpl 2017;23:S27-33. [DOI: 10.1002/lt.24862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Qu Z, Krauth C, Amelung VE, Kaltenborn A, Gwiasda J, Harries L, Beneke J, Schrem H, Liersch S. Decision modelling for economic evaluation of liver transplantation. World J Hepatol 2018; 10(11): 837-848 [PMID: 30533184 DOI: 10.4254/wjh.v10.i11.837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
51 Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, Zheng S, Xu X. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int 2020;33:697-712. [PMID: 31985857 DOI: 10.1111/tri.13585] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
52 Yang K, Sung PS, You YK, Kim DG, Oh JS, Chun HJ, Jang JW, Bae SH, Choi JY, Yoon SK. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response. HPB 2019;21:1718-26. [DOI: 10.1016/j.hpb.2019.04.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
53 Dumortier J, Besch C, Moga L, Coilly A, Conti F, Corpechot C, Bello AD, Faitot F, Francoz C, Hilleret MN, Houssel-Debry P, Jezequel C, Lavayssière L, Neau-Cransac M, Erard-Poinsot D, de Lédinghen V, Bourlière M, Bureau C, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION. Clin Res Hepatol Gastroenterol 2021;:101774. [PMID: 34332131 DOI: 10.1016/j.clinre.2021.101774] [Reference Citation Analysis]
54 Lerut J, Foguenne M, Lai Q. Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updates Surg 2021. [PMID: 34003479 DOI: 10.1007/s13304-021-01078-4] [Reference Citation Analysis]
55 Bi J, Yang L, Wang T, Zhang J, Li T, Ren Y, Wang M, Chen X, Lv Y, Wu R. Irisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver Injury. Oxid Med Cell Longev 2020;2020:6946037. [PMID: 31976032 DOI: 10.1155/2020/6946037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
56 方淼, 郑文杰, 姚敏, 董志珍, 姚登福. 肝癌特异诊断新标志物发现及其临床应用前景. 世界华人消化杂志 2017; 25(10): 865-873 [DOI: 10.11569/wcjd.v25.i10.865] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Saberi B, Garonzik-Wang J, Ma M, Ajayi T, Kim A, Luu H, Jakhete N, Pustavoitau A, Anders RA, Georgiades C, Kamel I, Ottmann S, Philosophe B, Cameron AM, Gurakar A. Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2020;18:463-9. [PMID: 30084757 DOI: 10.6002/ect.2017.0288] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
58 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
59 Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
60 Chen Y, Mu S, Wang J, Wu A. Chronic severe hepatitis and preoperative creatinine are independent risk factors for acute kidney injury after liver transplantation. Ann Transl Med 2020;8:1663. [PMID: 33490175 DOI: 10.21037/atm-20-7680] [Reference Citation Analysis]
61 Bhatti ABH, Hassan M, Rana A, Khan NY, Khan ZA, Zia HH. Risk Score Model for Liver Transplant Outcomes after Preoperative Locoregional Therapy for Hepatocellular Carcinoma. J Gastrointest Cancer 2020. [PMID: 33184772 DOI: 10.1007/s12029-020-00554-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Pan YX, Fu YZ, Hu DD, Long Q, Wang JC, Xi M, Liu SL, Xu L, Liu MZ, Chen MS, Zhang YJ. Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol. 2020;10:1639. [PMID: 33194569 DOI: 10.3389/fonc.2020.01639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
63 Chagas AL, Mattos AA, Diniz MA, Felga GEG, Boin IFSF, Silva RCMA, Silva RF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study. Ann Hepatol 2021;22:100294. [PMID: 33276136 DOI: 10.1016/j.aohep.2020.100294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Ghinolfi D, Rreka E, Pezzati D, Filipponi F, De Simone P. Perfusion machines and hepatocellular carcinoma: a good match between a marginal organ and an advanced disease? Transl Gastroenterol Hepatol 2017;2:87. [PMID: 29264425 DOI: 10.21037/tgh.2017.10.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
65 Yadav DK, Hua YF, Bai X, Lou J, Que R, Gao S, Zhang Y, Wang J, Xie Q, Edoo MIA, Chutturghoon VK, Liang T. ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2019;2019:8589402. [PMID: 31285743 DOI: 10.1155/2019/8589402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
66 Chen S, Ma W, Shen L, Wu Y, Qi H, Cao F, Huang T, Fan W. Recurrence Beyond the Milan Criteria of HBV-Related Single Hepatocellular Carcinoma of 2-3 cm: Comparison of Resection and Ablation. Front Oncol 2021;11:757149. [PMID: 34733791 DOI: 10.3389/fonc.2021.757149] [Reference Citation Analysis]
67 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
68 D'Souza JC, Sultan LR, Hunt SJ, Gade TP, Karmacharya MB, Schultz SM, Brice AK, Wood AKW, Sehgal CM. Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma. Nanotheranostics 2019;3:331-41. [PMID: 31687321 DOI: 10.7150/ntno.39514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
69 Hafeez Bhatti AB, Qureshi AI, Tahir R, Almas T, Rana A. Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes. Ann Med Surg (Lond) 2021;68:102552. [PMID: 34295467 DOI: 10.1016/j.amsu.2021.102552] [Reference Citation Analysis]
70 Chagas AL, Felga GEG, Diniz MA, Silva RF, Mattos AA, Silva RCMA, Boin IFSF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol 2019;31:1148-56. [PMID: 31247632 DOI: 10.1097/MEG.0000000000001448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
71 Bi Y, Li J, Yang Y, Wang Q, Wang Q, Zhang X, Dong G, Wang Y, Duan Z, Shu Z, Liu T, Chen Y, Zhang K, Hong F. Human liver stem cells attenuate concanavalin A-induced acute liver injury by modulating myeloid-derived suppressor cells and CD4+ T cells in mice. Stem Cell Res Ther 2019;10:22. [PMID: 30635035 DOI: 10.1186/s13287-018-1128-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Chen Y, Wang G, Xu H, Wang H, Bai D. Identification of a Novel Metastasis-Related miRNAs-Based Signature for Predicting the Prognosis of Hepatocellular Carcinoma. J Oncol 2021;2021:6629633. [PMID: 33603784 DOI: 10.1155/2021/6629633] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
73 Ye F, Huang W, Xue Y, Tang E, Wang M, Shi F, Wei D, Han Y, Chen P, Zhang X, Yu D. Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. J Hepatocell Carcinoma 2021;8:285-300. [PMID: 33948441 DOI: 10.2147/JHC.S306966] [Reference Citation Analysis]
74 Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, Chen CZ, Zheng SS. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:365-70. [PMID: 32553774 DOI: 10.1016/j.hbpd.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
76 Chen M, Chen Z, Lin X, Hong X, Ma Y, Huang C, He X, Ju W. Application of ischaemia-free liver transplantation improves prognosis of patients with steatotic donor livers - a retrospective study.Transpl Int. 2021;34:1261-1270. [PMID: 33484201 DOI: 10.1111/tri.13828] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Freeman AJ, Sellers ZM, Mazariegos G, Kelly A, Saiman L, Mallory G, Ling SC, Narkewicz MR, Leung DH. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease. Liver Transpl 2019;25:640-57. [PMID: 30697907 DOI: 10.1002/lt.25421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
78 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
79 Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann Surg 2021;273:483-93. [PMID: 33065633 DOI: 10.1097/SLA.0000000000004071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
80 Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, Otto G, Zimmermann T, Galle PR. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United European Gastroenterol J 2019;7:838-49. [PMID: 31316788 DOI: 10.1177/2050640619840221] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
81 Cusumano C, De Carlis L, Centonze L, Lesourd R, Levi Sandri GB, Lauterio A, De Carlis R, Ferla F, Di Sandro S, Camus C, Jézéquel C, Bardou-Jacquet E, Rayar M. Advanced donor age does not increase risk of hepatocellular carcinoma recurrence after liver transplantation: a retrospective two-centre analysis using competing risk analysis. Transpl Int 2021. [PMID: 34145653 DOI: 10.1111/tri.13950] [Reference Citation Analysis]
82 Sladky VC, Knapp K, Szabo TG, Braun VZ, Bongiovanni L, van den Bos H, Spierings DC, Westendorp B, Curinha A, Stojakovic T, Scharnagl H, Timelthaler G, Tsuchia K, Pinter M, Semmler G, Foijer F, de Bruin A, Reiberger T, Rohr-Udilova N, Villunger A. PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. EMBO Rep 2020;21:e50893. [PMID: 33225610 DOI: 10.15252/embr.202050893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
83 Chen X, Xu J, Wang P, Shang L, Guo J, Huang L, Jiang YA, Chen J, Chen H, Shang Y, Zhang Q. Metallophosphoesterase 1, a novel candidate gene in hepatocellular carcinoma malignancy and recurrence. Cancer Biol Ther 2020;21:1005-13. [PMID: 33054568 DOI: 10.1080/15384047.2020.1824480] [Reference Citation Analysis]
84 Hafeez Bhatti AB, Tahir R, Qureshi NR, Mamoon N, Khan NY, Zia HH. Living donor liver transplantation for intra hepatic cholangiocarcinoma. Ann Med Surg (Lond) 2020;57:82-4. [PMID: 32728435 DOI: 10.1016/j.amsu.2020.07.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Kong F, Jin M, Cao D, Jia Z, Liu Y, Jiang J. Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma. PeerJ 2020;8:e9949. [PMID: 32995093 DOI: 10.7717/peerj.9949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
86 Gorgen A, Rosales R, Sadler E, Beecroft R, Knox J, Dawson LA, Ghanekar A, Grant D, Greig PD, Sapisochin G. Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Transplantation 2019;103:2136-43. [DOI: 10.1097/tp.0000000000002616] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Goldaracena N, Barbas AS. Living donor liver transplantation. Curr Opin Organ Transplant. 2019;24:131-137. [PMID: 30694993 DOI: 10.1097/mot.0000000000000610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
88 Yu H, Bai Y, Xu C, He X, Liu Q, Ma D, A Y. The tissue expression levels of SUMO1P 3 may be a reliable prognostic biomarker to predict the clinical outcomes in patients with HCC. Medicine (Baltimore) 2020;99:e21291. [PMID: 33181633 DOI: 10.1097/MD.0000000000021291] [Reference Citation Analysis]
89 Malek Hosseini SA, Nikeghbalian S, Salahi H, Kazemi K, Shemsaeifar A, Bahador A, Dehghani M, Imanieh MH, Tabrizi R, Lankarani KB. Evolution of Liver Transplantation Program in Shiraz, Iran. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.60745] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
90 Zhang N, Jin W, Zhou S, Yang JD, Harmsen WS, Giama NH, Wongjarupong N, Heimbach JK, Watt KD, Malhi H, Therneau TM, Roberts LR. Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. Cancer Med 2018;7:5870-8. [PMID: 30453389 DOI: 10.1002/cam4.1797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
91 Wong TCL, Ng KKC, Fung JYY, Chan AAC, Cheung T, Chok KSH, Dai JWC, Lo C. Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses. Ann Surg Oncol 2019;26:1454-62. [DOI: 10.1245/s10434-019-07206-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
92 Ma Z, Yan H, Wang Y, Yang Y, Li X, Shi A, Jing-wen X, Yu-bao L, Li L, Wang X. Proteomics analysis demonstrating rosmarinic acid suppresses cell growth by blocking the glycolytic pathway in human HepG2 cells. Biomedicine & Pharmacotherapy 2018;105:334-49. [DOI: 10.1016/j.biopha.2018.05.129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
93 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
94 Li M, Tang Y, Wang D, Zhai X, Shen H, Zhong C, Yao M, Jin A, Zhou Z, Zhou S, Fan J, Ling CQ, Ling C. Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma. Mol Ther 2021:S1525-0016(21)00467-6. [PMID: 34547466 DOI: 10.1016/j.ymthe.2021.09.012] [Reference Citation Analysis]
95 Lau KCK, Osiowy C, Giles E, Lusina B, van Marle G, Burak KW, Coffin CS. Deep sequencing shows low-level oncogenic hepatitis B virus variants persists post-liver transplant despite potent anti-HBV prophylaxis. J Viral Hepat 2018;25:724-32. [DOI: 10.1111/jvh.12860] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
96 Xu X, Chen J, Wei Q, Liu Z, Yang Z, Zhang M, Wang G, Gao J, Yang Z, Guo W, Xing T, Shao Z, Xie Q, Zheng S. Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018 edition). Hepatobiliary & Pancreatic Diseases International 2019;18:307-12. [DOI: 10.1016/j.hbpd.2019.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
97 Chotai P, Matsuoka L. Reassessing the role of liver transplantation for patients with metastatic colorectal cancer to the liver. Curr Opin Organ Transplant 2019;24:118-20. [PMID: 30694992 DOI: 10.1097/MOT.0000000000000611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Hue JJ, Rocha FG, Ammori JB, Hardacre JM, Rothermel LD, Chavin KD, Winter JM, Ocuin LM. A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the National Cancer Database. J Surg Oncol 2021;123:949-56. [PMID: 33400841 DOI: 10.1002/jso.26370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
100 Liu ZG, Chen XH, Yu ZJ, Lv J, Ren ZG. Recent progress in pulsed electric field ablation for liver cancer. World J Gastroenterol 2020; 26(24): 3421-3431 [PMID: 32655266 DOI: 10.3748/wjg.v26.i24.3421] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Chen Z, Lin X, Chen C, Chen Y, Zhao Q, Wu L, Wang D, Ma Y, Ju W, Chen M, He X. Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation. Ann Transl Med. 2020;8:1067. [PMID: 33145286 DOI: 10.21037/atm-20-2751] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
102 Liao W, Fan L, Zheng Z, Liu H, Deng H, Li M, Liu F, Yang A. Ziyuglycoside II exerts antiproliferative and antimetastasis effects on hepatocellular carcinoma cells. Anticancer Drugs 2020;31:819-27. [PMID: 32097137 DOI: 10.1097/CAD.0000000000000918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Montano-Loza AJ, Mazurak VC, Ebadi M, Meza-Junco J, Sawyer MB, Baracos VE, Kneteman N. Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology 2018;67:914-23. [PMID: 29023899 DOI: 10.1002/hep.29578] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
104 Hibi T, Sapisochin G. What is transplant oncology? Surgery. 2019;165:281-285. [PMID: 30471780 DOI: 10.1016/j.surg.2018.10.024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
105 Zhang W, Huang J, Tang Y, Yang Y, Hu H. Inhibition of fatty acid synthase (FASN) affects the proliferation and apoptosis of HepG2 hepatoma carcinoma cells via the β-catenin/C-myc signaling pathway. Ann Hepatol 2020;19:411-6. [PMID: 32536483 DOI: 10.1016/j.aohep.2020.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
106 Mazzaferro V, Battiston C, Sposito C. Pro (With Caution): Extended oncologic indications in liver transplantation: Mazzaferro et al. Liver Transpl 2018;24:98-103. [DOI: 10.1002/lt.24963] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
107 Williams CH, Hickle K, Bakke K, Jamshed S, Bozorgzadeh A. Hepatic Epithelioid Angiomyolipoma Treated with Laparoscopic Resection: Case Report and Review of the Literature. Case Reports Hepatol 2019;2019:2362618. [PMID: 31355023 DOI: 10.1155/2019/2362618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021; 13(5): 392-405 [PMID: 34122730 DOI: 10.4240/wjgs.v13.i5.392] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
109 Kim AY, Sinn DH, Jeong WK, Kim YK, Kang TW, Ha SY, Park CK, Choi GS, Kim JM, Kwon CHD, Joh JW, Kim MJ, Sohn I, Jung SH, Paik SW, Lee WJ. Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. J Hepatol. 2018;68:1144-1152. [PMID: 29410377 DOI: 10.1016/j.jhep.2018.01.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
110 Désert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, Bellaud P, Perret C, Clément B, Lê Cao KA, Musso O. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017;66:1502-18. [PMID: 28498607 DOI: 10.1002/hep.29254] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
111 Yang Y, Sun M, Yao W, Wang F, Li X, Wang W, Li J, Gao Z, Qiu L, You R, Yang C, Ba Q, Wang H. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer 2020;8:e000317. [PMID: 32179631 DOI: 10.1136/jitc-2019-000317] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
112 Wang P, Xu Y, Sun Y, Cheng J, Zhou K, Wu S, Hu B, Zhang Z, Guo W, Cao Y, Huang X, Zhou J, Fan J, Yang X. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int 2021;41:562-73. [DOI: 10.1111/liv.14734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
113 Muaddi H, Al-Adra DP, Beecroft R, Ghanekar A, Moulton CA, Doyle A, Selzner M, Wei A, McGilvray ID, Gallinger S, Grant DR, Cattral MS, Greig PD, Kachura J, Cleary SP, Sapisochin G. Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent. Ann Surg Oncol. 2018;25:991-999. [PMID: 29327179 DOI: 10.1245/s10434-017-6329-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
114 Pozo-laderas J, Guler I, Rodríguez-perálvarez M, Robles J, Mula A, López-cillero P, de la Fuente C. Early postoperative mortality in liver transplant recipients involving indications other than hepatocellular carcinoma. A retrospective cohort study. Medicina Intensiva 2021;45:395-410. [DOI: 10.1016/j.medin.2020.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Glinka J, Ardiles V, Pekolj J, Mattera J, Sanchez Clariá R, de Santibañes E, de Santibañes M. Liver transplantation for non-resectable colorectal liver metastasis: where we are and where we are going. Langenbecks Arch Surg 2020;405:255-64. [PMID: 32333096 DOI: 10.1007/s00423-020-01883-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Hu J, Cai D, Zhao Z, Zhong GC, Gong J. Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway. Front Oncol 2021;11:659676. [PMID: 33937074 DOI: 10.3389/fonc.2021.659676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1963] [Article Influence: 707.3] [Reference Citation Analysis]
118 Guo J, Shirozu K, Akahoshi T, Mizuta Y, Murata M, Yamaura K. The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A. Int Immunopharmacol 2020;83:106462. [PMID: 32251961 DOI: 10.1016/j.intimp.2020.106462] [Reference Citation Analysis]
119 Chen H, Cheng H, Dai Q, Cheng Y, Zhang Y, Li D, Sun Y, Mao J, Ren K, Chu C, Liu G. A superstable homogeneous lipiodol-ICG formulation for locoregional hepatocellular carcinoma treatment.J Control Release. 2020;323:635-643. [PMID: 32302761 DOI: 10.1016/j.jconrel.2020.04.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
120 Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M. New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transpl 2019;25:311-22. [PMID: 30317696 DOI: 10.1002/lt.25354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
121 Liu X, Hou Y, Wang X, Yu L, Wang X, Jiang L, Yang Z. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatol Int 2020;14:567-76. [DOI: 10.1007/s12072-020-10046-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
122 Lee SK, Jang JW, Nam H, Sung PS, Kim HY, Kwon JH, Lee SW, Song DS, Kim CW, Song MJ, Choi HJ, You YK, Bae SH, Choi JY, Yoon SK. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatol Int 2021;15:137-45. [PMID: 33496932 DOI: 10.1007/s12072-020-10131-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Ma E, Li J, Xing H, Li R, Shen C, Zhang Q, Ma Z, Tao Y, Qin L, Zhao J, Wang Z. Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. Ann Transl Med 2021;9:468. [PMID: 33850865 DOI: 10.21037/atm-21-334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology 2021:S0016-5085(21)03284-4. [PMID: 34331914 DOI: 10.1053/j.gastro.2021.07.033] [Reference Citation Analysis]
125 Rodríguez-perálvarez M, Guerrero M, Barrera L, Ferrín G, Álamo JM, Ayllón MD, Artacho GS, Montero JL, Briceño J, Bernal C, Padillo J, Marín-gómez LM, Pascasio JM, Poyato A, Gómez-bravo MA, De la Mata M. Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Transplantation 2018;102:2056-64. [DOI: 10.1097/tp.0000000000002270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
126 Kalisvaart M, de Haan JE, Polak WG, Metselaar HJ, Wijnhoven BPL, IJzermans JNM, de Jonge J. Comparison of Postoperative Outcomes Between Donation After Circulatory Death and Donation After Brain Death Liver Transplantation Using the Comprehensive Complication Index. Ann Surg. 2017;266:772-778. [PMID: 28742700 DOI: 10.1097/sla.0000000000002419] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
127 Yoon YI, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000. [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
128 Bonferoni MC, Gavini E, Rassu G, Maestri M, Giunchedi P. Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting. Nanomaterials (Basel) 2020;10:E870. [PMID: 32365938 DOI: 10.3390/nano10050870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
129 Al-Ameri AAM, Wei X, Lin L, Shao Z, Guo H, Xie H, Zhou L, Zheng S, Xu X. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. BMC Cancer. 2019;19:1136. [PMID: 31752756 DOI: 10.1186/s12885-019-6343-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
130 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
131 Franken LC, Vuijk FA, Soer EC, Roos E, Erdmann JI, Hooijer GKJ, Vahrmeijer AL, Gambhir SS, van Gulik TM, Sarasqueta AF, Verheij J, Swijnenburg RJ. Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC. Eur J Surg Oncol 2021;47:628-34. [PMID: 33069505 DOI: 10.1016/j.ejso.2020.09.026] [Reference Citation Analysis]
132 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
133 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
134 Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation 2020;104:2087-96. [PMID: 31978002 DOI: 10.1097/TP.0000000000003115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien P. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 23.0] [Reference Citation Analysis]
136 Wang W, Chen G, Wang B, Yuan Z, Liu G, Niu B, Chen Y, Zhou S, He J, Xue H. Long non-coding RNA BZRAP1-AS1 silencing suppresses tumor angiogenesis in hepatocellular carcinoma by mediating THBS1 methylation. J Transl Med 2019;17:421. [PMID: 31847842 DOI: 10.1186/s12967-019-02145-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
137 Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1143-9. [PMID: 32217940 DOI: 10.1097/TP.0000000000003196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
138 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Gorgen A, Muaddi H, Zhang W, McGilvray I, Gallinger S, Sapisochin G. The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. Can J Gastroenterol Hepatol. 2018;2018:9531925. [PMID: 29623268 DOI: 10.1155/2018/9531925] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
140 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Pagano D, Barbàra M, Seidita A, Cintorino D, di Francesco F, Petridis I, Calamia S, Russelli G, Gruttadauria S. Impact of Extended-Criteria Donor Liver Grafts on Benchmark Metrics of Clinical Outcome After Liver Transplantation: A Single Center Experience. Transplantation Proceedings 2020;52:1588-92. [DOI: 10.1016/j.transproceed.2020.02.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
142 Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. Liver Transpl 2020;26:1100-11. [PMID: 32531867 DOI: 10.1002/lt.25819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
143 Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, Jones K, Leithead J, Masson S, Menon K, Mirza D, Neuberger J, Prasad R, Pratt A, Prentice W, Shepherd L, Simpson K, Thorburn D, Westbrook R, Tripathi D. Adult liver transplantation: A UK clinical guideline - part 1: pre-operation. Frontline Gastroenterol 2020;11:375-84. [PMID: 32879721 DOI: 10.1136/flgastro-2019-101215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
144 Rodríguez-Perálvarez M, Gómez-Bravo MÁ, Sánchez-Antolín G, De la Rosa G, Bilbao I, Colmenero J; Spanish Society of Liver Transplantation (SETH) Consensus Panel. Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. Transplantation 2021;105:602-7. [PMID: 32345868 DOI: 10.1097/TP.0000000000003281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
145 Gorgen A, Prediger C, Prediger JE, Chedid MF, Backes AN, de Araujo A, Grezzana-Filho TJM, Leipnitz I, Chedid AD, Alvares-da-Silva MR, Sapisochin G, Kruel CRP. Serum Factor V Is a Continuous Biomarker of Graft Dysfunction and a Predictor of Graft Loss After Liver Transplantation. Transplantation 2019;103:944-51. [PMID: 30130328 DOI: 10.1097/TP.0000000000002429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
146 Kornberg A, Witt U, Schernhammer M, Kornberg J, Müller K, Friess H, Thrum K. The role of preoperative albumin‐bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma. J Surg Oncol 2019;120:1126-36. [DOI: 10.1002/jso.25721] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]